|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Baylor Research Institute |
|---|---|
| Information provided by: | Baylor Research Institute |
| ClinicalTrials.gov Identifier: | NCT00947960 |
Purpose
The purpose of the study is to determine is triheptanoin is an effective treatment for the symptoms of Adult Polyglucosan Body Disease.
| Condition | Intervention | Phase |
|---|---|---|
|
Adult Polyglucoson Body Disease Glycogen Brancher Enzyme Deficiency Glycogen Storage Disease Type IV |
Dietary Supplement: Triheptanoin Dietary Supplement: Vegetable Oil |
Phase II |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | A Treatment Trial of Triheptanoin in Patients With Adult Polyglucosan Body Disease - A Randomized Controlled Study |
| Estimated Enrollment: | 18 |
| Study Start Date: | June 2009 |
| Estimated Study Completion Date: | December 2014 |
| Estimated Primary Completion Date: | December 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: T1 |
Dietary Supplement: Triheptanoin
1-2g/kg of body weight per day divided into 4 doses per day.
|
| Placebo Comparator: T2 |
Dietary Supplement: Vegetable Oil
1-2g/kg of body weight per day divided into 4 doses.
|
Adult polyglucosan disease is a progressive neurogenetic disorder characterized by neurogenic bladder, progressive difficulty with walking, and sensory abnormalities in the lower extremities which typically present in the 4th or 5th decade of life. The pathogenesis of the disease includes the accumulation of intracellular polyglucosan bodies (amylopectin-like polysaccharides) in the peripheral nerves as well as the central nervous system cells and is often associated with brancher enzyme deficiency which causes improper glycogen formation. It is hypothesized that decreased glycogen degradation leads to energy deficit in the nervous system cells. Therefore, anaplerotic therapy may supply needed substrate to the citric acid cycle to correct the energy deficit. This intervention may slow, halt or reverse the progression of the disease, for which there is no effective treatment. The trial involves 18 subjects ingesting a diet supplemented with triheptanoin, a 7 carbon triglyceride or a placebo of vegetable oil at a dose of 1-2 g/kg/24 hours in a randomized crossover controlled double blind study. The study lasts one year with patients receiving triheptanoin for 6 mo and the placebo oil for 6 mo. Safety monitoring includes urine organic acids and acyl carnitine profile.
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Mary Wallace, MSRD/LD, CCRC | 214-820-4752 | MaryWall@Baylorhealth.edu |
| Contact: Caren Swift, RN, BSN | 214-820-4857 | Caren.Swift@BaylorHealth.edu |
| France | |
| Department of Genetics, Groupe Hospitalier Pitié-Salpêtrière | Recruiting |
| Paris, France, 75013 | |
| Contact: Fanny Mochel, MD, PhD + 33 1 57 27 46 82 fanny.mochel@upmc.fr | |
| Contact: Daisy Rinaldi, PhD + 33 1 57 27 46 78 daisyrinaldi@free.fr | |
| Principal Investigator: Fanny Mochel, M.D., PhD | |
| Principal Investigator: | Raphael Schiffmann, M.D, M.H.Sc | Institute of Metabolic Disease |
More Information
| Responsible Party: | Raphael Schiffmann, M.D., M.H.Sc., Institute of Metabolic Disease , Baylor Research Institute |
| ClinicalTrials.gov Identifier: | NCT00947960 History of Changes |
| Other Study ID Numbers: | 009-103 |
| Study First Received: | July 24, 2009 |
| Last Updated: | August 17, 2011 |
| Health Authority: | United States: Food and Drug Administration |
|
Adult Polyglucoson Body Disease (APBD) Glycogen Brancher Enzyme (GBE1) Deficiency |
|
Glycogen Storage Disease Glycogen Storage Disease Type IV Carbohydrate Metabolism, Inborn Errors |
Metabolism, Inborn Errors Genetic Diseases, Inborn Metabolic Diseases |